Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Clinical Trials
4 recruiting trials for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Eligibility criteria explained in plain English.
TrialFinderData lists 4 Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Phase 1 is the largest group at 75% (3 studies); the largest phase groups are Phase 1: 3, Phase 2: 1.
Research is led by China Immunotech (Beijing) Biotechnology Co., Ltd. (3), Alexion Pharmaceuticals, Inc. (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is YTS109 cell (drug, 3 trials), followed by Placebo, Tarperprumig.
Track Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), including LN and...
A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), including LN and...
A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), Systemic Sclerosis...
Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated...
The primary objective of this study is to evaluate the safety and tolerability of tarperprumig in participants with newly diagnosed or relapsing anti-neutrophil cytoplasmic...
Explore Other Conditions
Frequently Asked Questions
There are currently 4 clinical trials for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, with 4 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.